Weekly Digest – January 2025 Weekly Digest – January 2025 29 Jan 2025: Vincerx Pharma and Oqory highlight promising data for Oqory’s TROP2 ADC, OQY-3258 Vincerx Pharma and Oqory highlighted Phase 1a/1b data for OQY-3258 It proposed a merger to advance […]
Weekly Digest – January 2025 Weekly Digest – January 2025 27 Jan 2025: Innate Pharma announces first patient dosed in phase 1 study of its Nectin-4 targeting antibody drug conjugate IPH4502 in selected advanced solid tumors Innate Pharma began a […]
Weekly Digest – January 2025 Weekly Digest – January 2025 27 Jan 2025: Lantern Pharma unveils innovative AI-Powered module to improve the precision, cost and timelines of Antibody-Drug Conjugate development for cancer Lantern Pharma is advancing ADC development using its […]
Weekly Digest – January 2025 Weekly Digest – January 2025 22 Jan 2025: Zai Lab receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the treatment of Small Cell Lung Cancer (SCLC) Zai Lab’s First-in-class DLL3-targeting […]
Weekly Digest – January 2025 Weekly Digest – January 2025 20 Jan 2025: YL201 received another Breakthrough Therapy Designation for the treatment of R/M Nasopharyngeal Carcinoma MediLink receives CDE Breakthrough Therapy Designation for YL201 for recurrent/metastatic nasopharyngeal carcinoma following prior […]
Weekly Digest – January 2025 Weekly Digest – January 2025 17 Jan 2025: Datroway (Datopotamab deruxtecan) approved in the US for patients with previously treated metastatic HR+, HER2- Breast Cancer Datroway is approved by FDA for metastatic HR-positive, HER2-negative breast […]
Weekly Digest – January 2025 Weekly Digest – January 2025 21 Jan 2025: ArriVent BioPharma enters exclusive license with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers ArriVent BioPharma entered to exclusive license agreement […]
Weekly Digest – January 2025 Weekly Digest – January 2025 22 Jan 2025: Vincerx Pharma enters at-the-market equity offering deal Vincerx partnered with H.C. Wainwright & Co. for a $30 million at-the-market equity offering Recently, it terminated sales agreement with […]
Weekly Digest – January 2025 Weekly Digest – January 2025 20 Jan 2025: GI Innovation, LaNova Medicines sign MOU to develop combination therapy for pancreatic cancer GI Innovation & LaNova signed MOU to develop a pancreatic cancer combination therapy with […]
Weekly Digest – January 2025 Weekly Digest – January 2025 16 Jan 2025: Innovent receives NMPA Breakthrough Therapy Designation for IBI343 (anti-CLDN18.2 ADC) as monotherapy for advanced Pancreatic Cancer Innovent Biologics received Breakthrough Therapy Designation (BTD) from the NMPA for […]
